## SRPT: Sarepta Therapeutics, Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_10 at 3.4% in lower entry zone (3.0-6.0%), top quartile (84th pct) cross-sectional ranking. Caution: MRS_5 (-0.1%) diverging from MRS_10, watch for reversal. Outperforming sector by 6.8%. Caution: momentum weakening (-2.6% MRS).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($18.90)
- **If Wrong:** Exit if MRS_10 drops below entry zone or breaks stop
- **Invalidation:** MRS_10 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 4
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Sarepta Therapeutics grants $12 million equity award to CEO Douglas Ingram**
- Source: Investing.com | 20251208T130939 | Somewhat-Bullish | Relevance: 99%
-  Sarepta Therapeutics' Board of Directors granted CEO Douglas S. Ingram a $12 million equity award, his first since 2017. Half of the award consists of time-based restricted stock units vesting over three years, while the other half is performance-based, tied to Sarepta’s Incentive EBITDA over a two-year period. This award is detailed in an SEC filing and reflects the company's ongoing compensation strategy.

**2. Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Shares Bounce 26% But Its Business Still Trails The Industry**
- Source: 富途牛牛 | 20251207T135322 | Neutral | Relevance: 99%
-  Sarepta Therapeutics (NASDAQ:SRPT) experienced a 26% share price jump in the last month, yet its business growth still lags the industry. The company's price-to-sales (P/S) ratio of 1x is significantly lower than the industry average, suggesting potential undervaluation but also reflecting uninspiring revenue forecasts. Analysts predict a 16% annual revenue contraction for Sarepta over the next three years, contrasting with the broader industry's anticipated 130% expansion.

**3. Edgestream Partners L.P. Purchases 74,427 Shares of Sarepta Therapeutics, Inc. $SRPT**
- Source: MarketBeat | 20251207T045322 | Neutral | Relevance: 98%
- Edgestream Partners L.P. significantly increased its stake in Sarepta Therapeutics (NASDAQ:SRPT) by 870.3% in the second quarter, acquiring an additional 74,427 shares to hold a total of 82,979 shares valued at $1.42 million. Sarepta reported quarterly revenue of $399.36 million, exceeding estimates, but missed on EPS with ($0.13) against an expected $0.02. The stock has a consensus "Hold" rating from analysts with an average target price of $33.75.

**4. Sarepta Therapeutics (SRPT): Valuation Check After New ENDEAVOR Dosing Approval and SRP-1003 Pipeline Milestones**
- Source: Simply Wall Street | 20251207T045322 | Somewhat-Bullish | Relevance: 98%
- Sarepta Therapeutics (SRPT) recently achieved two clinical milestones: FDA approval for Cohort 8 dosing in its ENDEAVOR gene therapy study and progress in its SRP 1003 RNA program for myotonic dystrophy. Despite a recent 1-month share price return of 19.23%, the company has experienced a significant 82.63% decline in total shareholder return over the past year. While one valuation model suggests the stock is overvalued by 11.8%, another discounted cash flow model indicates it is deeply discounted, implying potential market overreaction to near-term risks.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 2 ($0.09M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 106.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Tudor Investment Cor: 65.7% (+135261.8%)
- Blackrock Inc.: 12.6% (+8.9%)
- Vanguard Group Inc: 10.3% (+18.1%)
- State Street Corpora: 5.1% (+13.0%)
- Erste Asset Manageme: 2.6% (+65.7%)

### Key Risks

1. Valuation stretched: PEG 159.2x requires aggressive growth execution.
2. High short interest (19.9%, 3.1 days to cover): squeeze risk or crowded bearish bet.
3. Long-term trend broken: trading 39.0% below SMA200.
4. Falling knife pattern: rapid decline without stabilization, catch risk elevated.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 159.25 signals overvaluation risk, limited margin of safety. Balance sheet: strong liquidity (3.0x). Revenue declining -25% YoY, concerning. Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $2.3B |
| Beta | 0.53 |
| 52W Range | $10.42 - $131.31 |
| Short Interest | 19.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 159.25 |
| Forward P/E | 6.6 |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 deteriorating from 6.0% to 3.4% (-2.6% in 5 days), indicating relative weakness vs NASDAQ. Currently in lower STRENGTH zone (3.0-6.0%), cross-sectional ranking at 84th percentile. MRS_5 (-0.1%) diverging from MRS_10 - short-term weakness emerging. Outperforming sector by 6.8pp, stock-specific strength. Below SMA200 (0.61x), long-term trend not supportive. MACD histogram positive (0.52), confirming momentum. RSI neutral at 57.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 3.40% (CS: 84) | Strong |
| RSI_14 | 57.0 | Neutral |
| MACD Histogram | 0.52 | Bullish |
| vs SMA20 | 1.136x | Above |
| vs SMA50 | 1.051x | Above |
| vs SMA200 | 0.610x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $21.86
- **Stop Loss:** $18.90 (13.5% risk)
- **Target:** $26.30 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 168
- **Position Value:** $3,672.48
- **Portfolio %:** 3.67%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-25 (Est: $-0.78)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.37 | $-0.13 | +65.0% |
| 2025Q2 | $1.16 | $2.02 | +73.9% |
| 2025Q1 | $-0.65 | $-3.42 | -426.6% |
| 2024Q4 | $2.06 | $1.90 | -7.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*